Amgen’s Imdylltra (Tarlatamab) Secures the MHRA’s Conditional Marketing Authorization as a 3L Treatment of ES-SCLC
Shots:
- The MHRA has granted conditional marketing authorization to Imdylltra for treating adults with ES-SCLC, whose disease progressed post prior 2 lines of treatment. Further evaluation is underway
- This authorization was supported by P-II (DeLLphi-301) study assessing Imdylltra (10mg, Q2W) in ES-SCLC patients (N=99). It showed ORR of 41% & mDoR of 9.7mos.
- Imdylltra (tarlatamab) is a bispecific T-cell engager that binds to DLL3 on tumor cells and CD3 on T cells, activating T cells to release inflammatory cytokines and cytotoxic proteins for the destruction of DLL3+ tumor cells
Ref: BussinesNewsWire| Image: Amgen
Related News:- Amgen Reports 52 Weeks Data from P-II Trial of Maritide in Obese People with or without Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
